- Sorrento Therapeutics (NASDAQ:SRNE) announces that the U.S. FDA has authorized the company's IND application for the Phase 1 clinical testing of its allogeneic anti-CD38 Dimeric Antigen Receptor (DAR) - T Cell therapy for relapsed or refractory multiple myeloma.
- The company highlighted that CD38 DAR-T cell therapy candidate showed strong cytotoxic activity in preclinical studies.
- DAR-T technology is designed to potentially provide a significant advancement to the timeliness and potency of treatments for patient populations who have already undergone multiple rounds of chemotherapy and are suffering from persistent disease.
- "We foresee the first 'Off-the-Shelf' DAR-T trial will open the door to numerous other DAR-T cell therapies for other indications to follow," CEO Henry Ji said.
- Shares up more than 3% premarket.